Muscular Dystrophies
Lancet 394:2025-2038, Mercuri, E.,et al, 2019
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Progressive Weakness with Respiratory Failure in a Patient with Sarcoidosis
Arch Neurol 69:534-537, Chaudhry,P.,et al, 2012
Prolonged Paralysis After Neuromuscular Blockage
Muscle & Nerve, 18:937-94295., Gooch,J., 1995
Anticonvulsant Hypersensitivity Syndrome
Arch Int Med 155:2285-2290, Vittorio,C.C.&Muglia,J.J., 1995
Eosinophilia-Myalgia Syndrome, A Clinical Case Series of 21 Patients
Arch Int Med 151:533-537, Philen,R.M.,et al, 1991
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Pembrolizumab-Induced Myasthenia Gravis
Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018
Serotonin Syndrome
BMJ 348:g1626, Buckley, N.A.,et al, 2014
ICU-Acquired Weakness and Recovery from Critical Illness
NEJM 370:1626-1635, Kress, J.P. & Hall, J.B., 2014
Disturbances of Cerebrospinal Fluid, Including Hydrocephalus, Pseudotumor Cerebri, and Low-Pressure Syndromes, Pseudotumor Cerebri
Adams & Victors Principles of Neurology, Chp 30, pg 628, Ropper, A.H.,et al, 2014
Clinicopathologic Conference,Necrotizing Noninflammatory Myopathy Consistent with Exposure to Statins
NEJM 36:944-954, Case 7-2012, 2012
Treatment of Early Onset Multiple Sclerosis With Subcutaneous Interferon Beta-1a
Neurol 64:888-890, 778, Pohl,D., et al, 2005
Respiratory Adverse Events Associated with Diazepam Rectal Gel
Neurol 64:1768-1770, Pellock,J.M. &Shinnar,S., 2005
Rhabdomyolysis: An Evaluation of 475 Hospitalized Patients
Medicine 84:377-385, Melli,G.,et al, 2005
Prolongation of Midazolam Half-Life After Sustained Infusion for Status Epilepticus
Neurol 54:1366-1368, Naritoku,D.K.&Sinha,S., 2000
Multiple Sclerosis, Side Effects of Interferon Beta Therapy and Their Management
Neurol 53:1622-1627, Walther,E.U.&Hohlfeld,R., 1999
Complications of Sedation with Midazolam in the Intensive Care Unit and a Comparison with Other Sedative Regimens
Crit Care Med 26:947-956, Shafer,A., 1998
Coma Induced by Abuse of Gamma-Hydroxybutyrate (GBH or Liquid Ecstasy) :A Case Report
BMJ 314:35-36, Thomas,G.,et al, 1997
Intravenous Immune Globulin Therapy for Neurologic Diseases
Ann Int Med 126:721-730, Dalakas,M.C., 1997
The Nondystrophic Myotonias
In Myology, McGraw-Hill, 2nd Ed, Ch49, p1291-13024., Rudel,R.,et al, 1994
Missed Neuroleptic Malignant Syndrome
BMJ 304:831-832, Renwick,D.S.,et al, 1992
Prolonged Weakness after Long-Term Infusion of Vecuronium Bromide
Ann Int Med 117:484-486, Kupfer,Y.,et al, 1992
Multistate Outbreak of Poisonings Associated with Illicit Use of Gamma Hydroxy Butyrate
JAMA 265:447-448, , 1991
Aggravation of Myasthenia Gravis by Erythromycin
J Pediatr 119:155-156, Absher,J.R.&Bale,J.F., 1991
Prolonged Paralysis after Treatment with Neuromuscular Junction Blocking Agents
Crit Care Med 19:1125-1131, Gooch,J.L.,et al, 1991
Myasthenia Gravis in Mothers and Their Newborns
Clin Obstet Gynecol 34:82-99, Plauche,W.C., 1991
Irregular Breathing
In Internal Medicine, Little, Brown & Co, Boston, 3rd Ed, p. 573-574, Cherniack,N.S., 1990
Retinitis Pigmentosa
Surv Ophthalmol 33:137-177, Pagon,R.A., 1988
Clinical Use and Toxicity of Intravenous Lidocaine, A Report from the Boston Collaborative Drug Surveillance Program
Am Heart J 92:168-173, Pfeifer,H.J.,et al, 1976
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Posterior Reversible Encephalopathy Syndrome
NEJM 388:2171-2178, Geocadin,R.G., 2023
Trial of Botulinum Toxin for Isolated or Essential Head Tremor
NEJM 389:1753-1765, Marques,A.,et al, 2023
A 48-Year-Old Woman with 6 Months of Vivid Visual Hallucinations
Neurol 99:166-171, Kizza, J.,et al, 2022
Tardive Diaphragmatic Tremor
Neurol 94:e656, Gupta, H.V., 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Looking Beyond the Usual
Delhi J Ophthal doi:7869/djo.555, Shakrawal, J.,et al, 2020
Acute Toxic Leukoencephalopathy: Etiologies, Imaging Findings, and Outcomes in 101 Patients
AJNR 40:267-275, Ozutemiz, C.,et al, 2019
Clinicopathologic Conference, Digitalis Toxicity
NEJM 378:1931-1938, Case 15-2018, 2018
Efficacy and Tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy
Neurol 91:82-90, Kanner, A.M.,et al, 2018
Efficacy and Tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy
Neurol 91:74-81, Kanner, A.M.,et al, 2018
Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy
Neurol 91:e359-e363, Rauer,S.,et al, 2018
Immune Checkpoint Inhibitor-Related Myositis and Myocarditis in Patients with Cancer
Neurol 91:e985-e994, Touat, M.,et al, 2018
Trial of Fingolimod Versus Interferon Beta-1a in Pediatric Multiple Sclerosis
NEJM 379:1017-1027, Chitnis, T.,et al, 2018
Use of Newer Disease-Modifying Therapies in Pediatric Multiple Sclerosis in the US
Neurol 91:e1778-e1787, Krysko, K.M.,et al, 2018
Tocilizumab Treatment for New Onset Refractory Status Epilepticus
Ann Neurol 84:940-945, Jun, J.,et al, 2018
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
NEJM 376:2011-2020, Devinsky, O.,et al, 2017
Statin-Associated Autoimmune Myopathy
NEJM 374:664-669, Mammen, A.L., 2016